Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate

Journal of Neurology

Volumn 243, Issue 3, 1996, Pages 269-273

  Czlonkowska, Anna ^a   Gajda, Jolanta ^a   Rodo, Maria ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

D penicillamine; Wilson's disease; Zinc sulphate

Indexed keywords

CHELATING AGENT; COPPER; PENICILLAMINE; ZINC SULFATE;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEADACHE; HUMAN; LEUKOPENIA; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRIORITY JOURNAL; RASH; TASTE DISORDER; THROMBOCYTOPENIA; WILSON DISEASE;

ADULT; HEPATOLENTICULAR DEGENERATION; HUMANS; PATIENT COMPLIANCE; PENICILLAMINE; TIME FACTORS; TREATMENT OUTCOME; ZINC SULFATE;

EID: 0030030935     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00868525     Document Type: Article

References (28)

1. Bachmann H, Lossner J, Kuhn H-J, Biesold D, Siegmund R, Kunath B, Willgerodt H, Teichmann B, Wieczorek W, Muhlau G, Tinschert K, Hitzschke B, Lakner K, Kallwellis G, Schmehl V (1989) Long-term care and management of Wilson's disease in the GDR. Eur Neurol 29:301-305
2. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P (1983) Oral zinc therapy for Wilson's disease. Ann Intern Med 99:314-320
3. Brewer GJ, Terry CA, Aisen AM, Hill GM (1987) Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 44:490-493
4. Brewer GJ, Turkay A, Yuzbasiyan-Gurkan V (1994) Development of neurologic symptoms in patient with asymptomatic Wilson's disease treated with penicillamine. Arch Neurol 51: 304-305
5. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink J, Aisen A (1994) Treatment of Wilson's disease with amonium tetrathiomolybate. Arch Neurol 51: 546-554
6. Cumings JN (1948) The copper and iron content of brain and liver in the normal and in hepatolenticular degeneration. Brain 71:410-415
7. Cumings JN (1951) The effect of BAL on hepatolenticular degeneration. Brain 74:20-22
8. Członkowska A (1975) Myasthenia syndrome during penicillamine treatment. BMJ 2, 726
9. Członkowska A, Galewicz A, Rodo M, Wehr H (1973) Observations on copper metabolism in Wilson's disease. Acta Univ Carol Med (Praha) 56/57:175-178
10. Członkowska A, Szleper M, Rodo M, Kuczyńska Zardzewialy A, Piłkowska E (1991) Zinc therapy in Wilson's disease. In: Członkowska A, Van den Hamer CJA (eds) Proceedings of the 5th Symposium on Wilson's disease. The Technical University, Delft, pp 43-48
11. Denning TR, Berrios GE (1989) Wilson's disease: clinical groups in 400 cases. Acta Neurol Scand 80:527-534
12. Denny Brown D, Porter H (1951) The effect of BAL (2,3 dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl J Med 245: 917-925
13. Giagheddu A, Demelia L, Puggioni G, Nurchi AM, Contu L, Pirari G, Doplano A, Rachele MG (1985) Epidemiologic study of hepatolenticular degeneration (Wilson's disease) in Sardinia (1902-1983). Acta Neurol Scand 72: 43-55
14. Hoogenraad TU, Van den Hamer CJA (1983) Three years of continuous zinc therapy in four patients with Wilson's disease. Acta Neurol Scand 67:356-364
15. Hoogenraad TU, Van Hattum J, Van den Hamer CJA (1987) Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 77:137-146
16. Lang ChJG, Rabas-Kolominksy P, Engelhardt A 81993) Fatal deterioration Wilson's disease after institution of oral zinc therapy. Arch Neurol 50: 1007-1008
17. Marsden CD (1987) Wilson's disease. QJ Med 248:959-966
18. Ravin HA (1961) An improved colorimetric enzymatic assay for ceruloplasmin. J Clin Lab Med 58:161-163
19. Scheinberg JH, Sternlieb I (1984) Wilson's disease. Major problems in internal medicine, vol XXIII. Saunders, Philadelphia
20. Scheinberg JH, Jaffe ME, Sternlieb I (1987) The use trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 317:209-213
21. Schouwink C (1961) Hepato-cerebral degeneration (in Dutch). MD thesis, University of Amsterdam. Van der Wiel, Arnheim
22. Strickland GT, Frommer D, Leu ML, Pollard R, Scherlock S, Cumings JN (1973) Wilson's disease in the United Kingdom and Taiwan. I. General characteristics of 142 cases and prognosis. II. A genetic analysis of 88 cases. QJ Med 42:619-638
23. Walshe JM (1956) Penicillamine. A new oral therapy for Wilson's disease. Am J Med 21:487-495
24. Walshe JM (1969) The management of penicillamine nephropathy in Wilson's disease. A new chelating agent. Lancet II: 1401-1402
25. Walshe JM (1975) Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 42:441-452
26. 4) as an anticopper agent in man. In: Scheinberg IH, Walshe JM (eds) Orphan drugs and orphan diseases. Manchester University Press, Manchester, pp 76-85
27. Walshe JM (1988) Wilson's disease: yesterday, today and tomorrow. Mov Disord 3:10-29
28. Walshe JM, Yealland M (1993) Chelation treatment of neurological Wilson's disease. Q J Med 86:197-204